Skip to main content
Premium Trial:

Request an Annual Quote

Stock Talk

In a Q&A posted at Market Playground, AlphaNorth Asset Management Chief Investment Officer Steven Palmer tells The Life Sciences Report's George Mack that when it comes to pharma and biotech investments, "it is all about risk versus reward." For that reason, Palmer says he generally errs on the side of investing in established, later-stage companies. "I try to stay away from the private life sciences companies because that really implies they are much earlier stage. The earlier stage you go in biotech, the higher the risk," he tells Mack.

Mack then asks whether investing in a biotech that has yet to move its product into the clinic is a good idea. "We look for companies that are working on products that have huge market potential and situations that we view as lower risk," Palmer tells him. "We also prefer companies that have multiple products. I view biotech similar to mining companies actually. Whether it is exploration success or clinical success, the rewards can be dramatic."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.